Cargando…

SAT489 Grave’s Disease Secondary To Alemtuzumabuse

Disclosure: M.S. Gong: None. D. Lee: None. R. Arceo-Mendoza: None. Introduction: We present a case of alemtuzumab-induced autoimmune thyroid disease in a patient with Multiple Sclerosis (MS). Clinical Case: A 42/F was evaluated by endocrine inpatient service for hyperthyroidism. She presented with t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gong, Michael Shifeng, Lee, David, Arceo-Mendoza, Rod Marianne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Thyroid
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554499/ http://dx.doi.org/10.1210/jendso/bvad114.1962

Ejemplares similares

SAT564 Metastatic Malignant Pleural Effusion In A Patient With Remote History Of FTC
por: Lee, David M, et al.
Publicado: (2023)

SAT-489 The Weary Beating Heart: Complications of Severe Hypothyroidism in a Mentally Ill Patient
por: Pagan, Nikita Limara Rabelo, et al.
Publicado: (2020)

SAT-476 Alemtuzumab Induced Graves Disease
por: Caputi, Rafael C, et al.
Publicado: (2020)

SAT462 TSI Versus TRAb In The Diagnosis Of Grave’s Disease
por: Ibrahim, Katherine, et al.
Publicado: (2023)

SAT-603 Graves' Disease and an Anterior Mediastinal Mass
por: Robbins, D'lorah, et al.
Publicado: (2019)

SAT-592 Amiodarone-Induced Cure Of Graves' Disease
por: Sharma, Eliza, et al.
Publicado: (2019)

SAT-605 Immune Thrombocytopenic Purpura in Graves' disease
por: Sajja, Puspalatha, et al.
Publicado: (2019)

SAT-582 Autoimmune Hepatitis Presenting with Graves Disease
por: Coy, Andres, et al.
Publicado: (2019)

SAT-428 Sex-Specific Risk Gene of Graves’ Disease
por: Zhao, Shuangxia, et al.
Publicado: (2020)

SAT-498 Graves’-Associated Takotsubo Cardiomyopathy: An Uncommon Condition
por: Mortensen, Michael, et al.
Publicado: (2020)

SUN-489 MetastaticThyroidCancer
por: Vásquez, Romyna La Rosa
Publicado: (2020)

SAT490 Graves’ Disease In Remission Aggravated By Himalayan Salt Consumption
por: Shakir, Mohamed K M, et al.
Publicado: (2023)

SAT-588 Unique Presentation of Postpartum Thyroiditis with Features of Graves' Disease
por: Havranova, Jana, et al.
Publicado: (2019)

SAT-429 Systemic Safety Analysis of Mycophenolate in Graves’ Orbitopathy
por: Lee, Alan C H, et al.
Publicado: (2020)

SAT-581 Graves' Disease and Hashimoto's Thyroiditis: Two Ends of a Spectrum
por: Morselli, Lisa, et al.
Publicado: (2019)

SAT-463 Thyrotoxicosis from Nivolumab in a Patient with Preexisting Graves’ Disease
por: Polavarapu, Preethi, et al.
Publicado: (2020)

SAT-413 Does Dipeptidyl Peptidase-4 Inhibitor Exacerbate Graves’ Disease?
por: Sekizaki, Tomonori, et al.
Publicado: (2020)

SAT-415 Clinical Performance of Thyroid-Stimulating Immunoglobulin for Graves′ Disease Diagnosis
por: Marui, Suemi, et al.
Publicado: (2020)

SAT-497 Conversion of Hashimoto’s Thyroiditis to Grave’s Disease: A Case Report
por: Wahedi, Tayba S, et al.
Publicado: (2020)

SAT474 A Case Report Of Moyamoya Disease Associated With Uncontrolled Graves' Disease
por: Tan, Zi, et al.
Publicado: (2023)

SAT-604 Immunoglobulin G4-related Disease In A Patient With Graves' Disease
por: Ozgen Saydam, Basak, et al.
Publicado: (2019)

SAT-554 Teprotumumab in Graves' Orbitopathy: Extended Outcome Analyses
por: Kahaly, George, et al.
Publicado: (2019)

SAT-459 A Grave Complication: Pulmonary Arterial Hypertension
por: Butt, Wajeeha Saeed, et al.
Publicado: (2020)

SAT-423 Anti-thyroid Drug Response in Graves’ Disease: Predictors of Biochemically Persistent Disease
por: El Kawkgi, Omar M, et al.
Publicado: (2020)

SAT488 Wolff-Chaikoff’s Revenge: There-and-Back Again Graves Thyrotoxicosis
por: Akofu, Anota, et al.
Publicado: (2023)

SAT-557 Functional Thyrotropin Receptor Antibodies Confirm a Novel Graves' Disease Animal Model
por: Diana, Tanja, et al.
Publicado: (2019)

SAT495 Persistent Euthyroid State in a Patient with Biochemical and Imaging Evidence of Graves' Disease
por: Antony, Mc Anto, et al.
Publicado: (2023)

SAT553 A Case of Metastatic Functional Papillary Thyroid Cancer in the Setting of Graves’ Disease
por: Manuel, Nicholas, et al.
Publicado: (2023)

SAT-518 Progression of Graves Disease to Hashimoto’s Thyroiditis Following Alemtuzumab Therapy for Multiple Sclerosis
por: Rapier, Brandon, et al.
Publicado: (2020)

SAT-456 Reduced Cholesterol Absorption and Synthesis Markers in Patients with Hyperthyroidism Due to Graves’ Disease
por: Nagamine, Tomoko, et al.
Publicado: (2020)

SAT461 Hearing-related Issues Associated With Graves’ Disease, Thyroid Eye Disease And Treatment With Teprotumumab
por: Smith, Terry J, et al.
Publicado: (2023)

SAT-471 A Rare Case of Pretibial Myxedema Preceding Graves’ Hyperthyroidism
por: Bao, Ginny W, et al.
Publicado: (2020)

SAT548 Incidental Papillary Thyroid Carcinoma Diagnosed After Total Thyroidectomy For Recurrent Grave's Disease
por: Perez-Martinez, Sebastian U, et al.
Publicado: (2023)

SAT-625 Dose-Dependent, Methimazole-Induced Agranulocytosis in a Pregnant Hispanic Woman with Grave's Disease
por: Bello, Fatimah, et al.
Publicado: (2019)

SAT-412 Genetic Susceptibility to Graves’ Disease Conferred by HLA-DQβ1 Position 57
por: Badenhoop, Klaus, et al.
Publicado: (2020)

SAT-422 Evaluation of the Siemens Thyroid Stimulating Immunoglobulin (TSI) Assay for Diagnosis and Prognosis of Graves’ Disease
por: Paul, Heather, et al.
Publicado: (2020)

SAT-482 Simultaneous Hashimoto/Graves Disease or Prolonged Hashitoxicosis? A Diagnostic Challenge with Therapeutic Implications
por: Penaherrera, Carlos A, et al.
Publicado: (2020)

SAT-606 Graves' Orbitopathy Treated with Kahaly's Protocol: IV High Dose Glucocorticoids
por: Patel, Bijal, et al.
Publicado: (2019)

FRI489 The Interplay Between Thyroid Nodular Disease And Insulin Resistance Indices In Pregnant Women
por: Jerzy Nowak, Andrzej, et al.
Publicado: (2023)

SAT-584 Pembrolizumab-Related Graves' Disease: A Rare Adverse Effect of an Anti-PD-1 Antibody Cancer Immunotherapy
por: Narayen, Garima, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_od65k160qvqp60s05eita8csa5